Ipamorelin vs tesamorelin

Ipamorelin stimulates the ghrelin receptor; tesamorelin stimulates the growth hormone-releasing factor receptor. Ipamorelin’s bowel-surgery trial observed earlier meal tolerance but did not establish a benefit over placebo. Tesamorelin reduced visceral abdominal fat in adults with HIV lipodystrophy and has an approved product for that setting. Their trials do not establish relative muscle growth, recovery or general weight-loss effects.

Research reviewed October 15, 2026. Educational information only.

Different receptors and different clinical questions

Ipamorelin is a synthetic five-residue peptide acting on the ghrelin-receptor system. Tesamorelin is a modified form of the 44-residue human growth hormone-releasing factor, also called GHRH, with an amino-terminal hexenoyl group. It stimulates the GHRH receptor on pituitary cells. Both can increase growth hormone, but their receptor inputs and molecular structures are different.

The difference is reflected in clinical development. Ipamorelin was tested for delayed return of gut function after bowel surgery. Tesamorelin was tested for excess fat inside the abdomen in adults with HIV lipodystrophy, a disorder of fat distribution. A trial that measures tolerating a meal and a trial that measures abdominal fat do not answer a shared question about which is more effective.

The main differences

What happened after bowel surgery with ipamorelin

Beck and colleagues enrolled 117 adults undergoing small- or large-bowel resection in a randomized, double-blind placebo-controlled trial. The safety and modified intention-to-treat analyses included 114 people. Investigators gave intravenous ipamorelin or placebo during the postoperative period and measured how long it took after the first study infusion for patients to tolerate a standardized solid meal.

The median time was 25.3 hours with ipamorelin and 32.6 hours with placebo. Patients assigned ipamorelin therefore tolerated the meal earlier numerically, but the comparison was too uncertain to establish an efficacy difference (P=0.15). The secondary analyses also did not establish differences. This result leaves the possible benefit unresolved; it does not prove that the two treatments have identical effects.

Any event that emerged during treatment was recorded in 87.5% of ipamorelin recipients and 94.8% of placebo recipients. Bowel-surgery patients commonly have postoperative events from many causes. These percentages alone cannot establish a lower drug-related risk, and the small trial cannot define uncommon or long-term harms.

What changed in abdominal fat with tesamorelin

In Falutz and colleagues’ randomized 2007 trial, 412 adults with HIV and abdominal fat accumulation received the original tesamorelin formulation or placebo for 26 weeks. Computed tomography measured visceral fat, the fat inside the abdomen around the organs. This compartment decreased 15.2% with tesamorelin and increased 5.0% with placebo (P<0.001). The comparison establishes an effect on visceral fat in the enrolled population.

A separate fifty-person trial in adults with HIV and abdominal fat accumulation measured liver fat as well as visceral fat. After six months, the liver lipid-to-water percentage changed by −2.0 percentage points with tesamorelin and +0.9 with placebo (P=0.003). These liver measurements are a different outcome from overall body weight, and the trial was not a comparison with ipamorelin.

The current Egrifta WR label indicates reduction of excess abdominal fat in adults with HIV lipodystrophy. It says the product is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Those boundaries matter because a reduction in visceral fat neither demonstrates general obesity treatment nor proves fewer heart attacks or strokes.

Pharmacokinetics: blood persistence and clinical effects

Gobburu and colleagues gave ipamorelin as short intravenous infusions to healthy men, with eight participants at each of five exposure levels. They measured both ipamorelin and growth hormone and estimated a terminal peptide half-life of about two hours. Growth hormone rose in a single episode with a peak around 0.67 hours. The abstract does not report the total number of unique participants across the five levels.

For tesamorelin, the current Egrifta WR label reports a mean elimination half-life of eleven minutes after a single subcutaneous administration in healthy adults. This estimate concerns a defined product and route. The original clinical trial formulation, Egrifta WR and Egrifta SV have formulation-specific exposure information; the label expressly states that WR and SV are not substitutable.

The ipamorelin and tesamorelin estimates come from different routes and studies. They describe the administered peptides’ blood disappearance, not how long a downstream tissue effect lasts. Neither estimate establishes superior fat reduction, recovery or muscle growth.

Animal selectivity and human safety are different findings

The original ipamorelin characterization used pituitary cells, rats and pigs. In the pig comparisons, ipamorelin stimulated growth hormone, while ACTH and cortisol responses were not established as higher than those with GHRH, even at high experimental exposures. ACTH signals the adrenal glands, which release cortisol as part of the stress response. The result describes endocrine selectivity in that model. It does not establish an absence of cortisol effects or adverse events in every human setting.

FDA’s current ipamorelin-acetate assessment identifies possible immune reactions related to aggregation or peptide impurities, difficulty characterizing unnatural amino acids and limited information for some injectable routes. It also notes serious adverse events, including deaths, in the intravenous gastric-motility literature. Such reports do not by themselves establish that ipamorelin caused the deaths, but they preclude treating the small postoperative trial as proof of general safety.

Tesamorelin’s product label provides a defined safety framework. It contraindicates use with active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy and known hypersensitivity to the product or excipients. Warnings include elevated IGF-1, fluid retention, glucose intolerance or diabetes and hypersensitivity. Its approved status concerns a particular benefit-risk assessment for HIV lipodystrophy and cannot establish a lower risk than ipamorelin for an untested purpose.

What can be compared responsibly

The clearest distinction is between the outcomes actually tested. Ipamorelin’s postoperative trial recorded a favorable numerical meal-tolerance difference with substantial uncertainty. Tesamorelin’s controlled HIV studies demonstrated a reduction in visceral fat, with separate studies measuring liver fat. No cited trial randomized people between the two compounds for muscle growth, recovery or general weight loss.

A shared increase in growth hormone does not bridge those differences in participants, preparation and outcome. For any further comparison, the relevant question is whether the same clinical outcome improves in the same population under a controlled study, with harms measured alongside it.

Frequently asked questions

Profiles and related reading

References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998;139(5):552–561. DOI: 10.1530/eje.0.1390552.

   In pigs, ipamorelin stimulated growth hormone while ACTH and cortisol responses were not established as higher than with growth hormone-releasing hormone (GHRH). ACTH signals the adrenal glands, which release cortisol during stress. GHRP-2 and GHRP-6 raised those hormones in the tested conditions.

2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999;16(9):1412–1416. DOI: 10.1023/a:1018955126402.

   Human serial measurements distinguish circulating ipamorelin from the modeled GH episode.

3. Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014;29(12):1527–1534. DOI: 10.1007/s00384-014-2030-8.

   After bowel surgery, median solid-meal tolerance occurred at 25.3 hours with intravenous ipamorelin and 32.6 hours with placebo; the earlier numerical time did not establish benefit (P=0.15).

4. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine. 2007;357(23):2359–2370. DOI: 10.1056/NEJMoa072375. PMID: 18057338.

   The original randomized HIV trial measured a selective visceral fat reduction and a substantial IGF-1 increase.

5. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. DOI: 10.1001/jama.2014.8334. PMID: 25038357.

   A six month HIV trial measured reductions in visceral and liver fat and an early fasting glucose rise.

6. Theratechnologies Inc. Egrifta WR (tesamorelin) prescribing information. DailyMed SPL version 2, effective 29 July 2026; prescribing text revised March 2025.

   Current WR labeling identifies the approved HIV lipodystrophy use, formulation distinction and eleven minute mean elimination half-life.

7. Theratechnologies Inc. Egrifta SV (tesamorelin) prescribing information. DailyMed, accessed 13 October 2026; prescribing information revised February 2024.

   SV labeling reports an eight minute mean elimination half-life after single subcutaneous administration in healthy subjects.

8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Agency safety assessment; accessed 2026-10-13.

   The agency identifies substance- and route-specific safety concerns and gaps for compounded peptides.

9. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, October 29, 2024. Agency presentation on ipamorelin-related substances.

   The clinical-effectiveness discussion retains the negative overall postoperative comparison.